Silexion wins Germany BfArM clearance to launch SIL204 Phase 2/3 pancreatic cancer trial

Biomotion Sciences. Ordinary Shares

Biomotion Sciences. Ordinary Shares

SLXN

0.00
  • Silexion won unconditional clearance from Germany’s BfArM to start its Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer.
  • The authorization positions the company to launch the study in Germany alongside previously secured approval in Israel.
  • First patient dosing is expected in the coming weeks, subject to site activation timelines.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Silexion Therapeutics Corp. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606230840PRIMZONEFULLFEED1001209180) on June 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.